REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in June:
Jefferies Global Healthcare Conference
Presentation Date: Wednesday, June 4, 2025 at 10:30 AM ET
Presentation Format: Corporate Presentation
Webcast: Here
Goldman Sachs 46th Healthcare Conference
Presentation Date: Tuesday, June 10, 2025 at 8:40 AM ET
Presentation Format: Corporate Presentation
Webcast: Here
A replay of both events will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The Company’s first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
| Last Trade: | US$48.36 |
| Daily Change: | -0.90 -1.83 |
| Daily Volume: | 288,040 |
| Market Cap: | US$2.600B |
November 24, 2025 November 04, 2025 October 13, 2025 August 06, 2025 July 10, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
